Literature DB >> 23954508

Are in situ formulations the keys for the therapeutic future of S-nitrosothiols?

Marianne Parent1, Ariane Boudier, François Dupuis, Cécile Nouvel, Anne Sapin, Isabelle Lartaud, Jean-Luc Six, Pierre Leroy, Philippe Maincent.   

Abstract

S-nitrosoglutathione (GSNO) and S-nitroso-N-acetylpenicillamine (SNAP) were formulated into in situ forming implants (ISI) and microparticles (ISM) using PLGA and either N-methyl-2-pyrrolidone (NMP) or triacetin. Physicochemical characterization was carried out, including the study of matrix structure and degradation. A strong correlation between drug hydrophobicity and the in vitro release profiles was observed: whatever the formulation, GSNO and SNAP were completely released after ca. 1 day and 1 week, respectively. Then, selected formulations (i.e., SNAP-loaded NMP formulations) demonstrated the ability to sustain the vasodilation effect of SNAP, as shown by monitoring the arterial pressure (telemetry) of Wistar rats after subcutaneous injection. Both ISI and ISM injections resulted in a 3-fold extended decrease in pulse arterial pressure compared with the unloaded drug, without significant decrease in the mean arterial pressure. Hence, the results emphasize the suitability of these formulations as drug delivery systems for S-nitrosothiols, widening their therapeutic potential.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Drug delivery systems; In situ implants; In situ microparticles; Nitric oxide donors; Pulse arterial pressure; S-nitrosothiols; Sustained release

Mesh:

Substances:

Year:  2013        PMID: 23954508     DOI: 10.1016/j.ejpb.2013.08.005

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  1 in total

1.  In Situ Microparticles Loaded with S-Nitrosoglutathione Protect from Stroke.

Authors:  Marianne Parent; Ariane Boudier; Julien Perrin; Claude Vigneron; Philippe Maincent; Nicolas Violle; Jean-François Bisson; Isabelle Lartaud; François Dupuis
Journal:  PLoS One       Date:  2015-12-08       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.